Methylome against cancers From innovation to a key business case December 8th, 2010 Dr. Sandra HUYGEN, PhD, MBA
Jul 16, 2015
Methylome against cancersFrom innovation to a key business case
December 8th, 2010
Dr. Sandra HUYGEN, PhD, MBA
Innovative Molecular Diagnostics Value Chain
PCR Methylation Oncology Diagnosis Personnalized med.
OutcomeObjectivesResources TechnologyInstrumentation
18 proves of concept IP rights on >300 biomarkers
and Companion Dx Outlicencing to Selfscreen Commercial deal with GSK-Bio Sample collection Publications (in prep.)
Partners
Budget - 3.739.054 €
Manpower - 20 FTEs
3.5 Y Dec 2010
2
July 2007
Synergies
MDxHealth
GSK-BioULg - Patho
Leading vaccine manufacturer
Antigen Specific Cancer Immunotherapies
development
MSP technologyPatented gene portfolio
Academic advisorsCommercial channels
Leading Europeangynecological cancer expertise Stored and prospective clinical
samples
Leading European cancer
expertise in particular in
cervical oncology and HPV
field
ULg - Gyneco
Innovation
Methylation Specific PCR (MSP) Technology
Methylation present in all cancersMethylation regulates gene expression
Specific genes methylated in each cancerAbnormal methylation of specific genes is correlatedwith cancer development
Sensitive detection in all sample typesDetects 1 cancer cell among 10,000 normal cells
One or few genes suffice for testsNo complicated algorithms, etc.
Technology runs on any PCREquipment already installed worldwide
Straight-forward testingAutomatable
Patented TechnologyBoth detection technology and individual genes (biomarkers)
Strategy & Business model
Commercial partners
Diagnostic & pharma companies
Service lab US: CLIA lab
Service lab Wallonia
Development
& test Clinical Trials & FDA
Approval
MassMarket Kit
Sales
Commercialization:
Service Lab Sales
Kit Dev. Kits sales
Service
Lab Dev.Prototype
definitionBiomarker
discoveryReg.
Review
Lab Service sales
Basic research Applied research Commercialization
OncoMethylomic project
Academic partnerships
MSP technology
Prototype
development
Clinical
verification
Organization,
Project management,
Partner rights & obligations
IP,
Access rights,
Publications,
Confidentiality,
Royalties & Fees
Legal framework
Consortium agreement Clinical Research
Agreements
Steering committee
Business development
Valorization committee
Executive committee
Task forces
BioWin RW – DGO6
Consortium organization
14
For further information
Sandra HUYGEN
Mobile: 0032/486.467.191